Spyre Therapeutics (SYRE) AI Stock Analysis

• Market Cap: $934.88M
• Dividend Yield: N/A
• Average Volume (3M): 534.57K
• Price to Earnings (P/E): 2.3
• Beta (1Y): 1.92
• Revenue Growth: -100.00%
• EPS Growth: 94.68%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.60
• Shares Outstanding: 60,353,560
• 10 Day Avg. Volume: 803,183
• 30 Day Avg. Volume: 534,570
• PEG Ratio: 0.71
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.47
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: 3.69
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $56.83
• Price Target Upside: 266.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 43 Neutral
• Price Target: ―

Spyre Therapeutics is facing significant financial challenges with consistent revenue and profitability issues. Its strong equity position is overshadowed by operational cash flow problems and persistent losses. Technically, the stock is under bearish pressure, and the valuation is complicated by a negative P/E ratio and lack of dividends. These factors combined result in a low overall stock score, reflecting the high-risk nature of investing in this biotechnology company.

Positive Factors

Clinical Development

SYRE continues to execute well against their strategy of developing combinations for inflammatory bowel disease, with supportive Ph 1 TL1A data, initiation of Ph 2, and an expanded approach in rheumatology.

Safety Profile

No serious adverse events were reported in the study, indicating a favorable safety profile for SYRE's products.

Negative Factors

Market Sentiment

Short interest in Spyre Therapeutics is relatively high at 23.6% of the float, which could indicate skepticism about the company’s prospects among some investors.

Pipeline Expansion Concerns

Today's stock reaction likely reflects some doubt on expanding pipeline focus and clinical development plans.

Spyre Therapeutics Business Overview & Revenue Model

Company Description

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

How the Company Makes Money

Spyre Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products. The company earns money by selling its approved drugs to healthcare providers, hospitals, and directly to patients through pharmacies. Additionally, Spyre may engage in strategic partnerships and collaborations with larger pharmaceutical companies for co-development, licensing, or distribution of its products, which can provide upfront payments, milestone payments, and royalties. The company's revenue model is also supported by research grants and funding for its clinical trials and development programs.

Spyre Therapeutics Financial Statement Overview

Summary

Spyre Therapeutics operates in the biotechnology industry with a high-risk financial profile characterized by consistent revenue challenges and profitability issues. The balance sheet reflects a strong equity position with no debt, but the lack of operational cash flow and persistent losses are concerning. The company needs significant revenue growth and profitability improvements to enhance its financial health.

Income Statement

Spyre Therapeutics has consistently struggled to generate revenue over the years, with recent data showing zero total revenue. The company has recorded negative EBIT and net income, leading to negative profit margins. Despite a slight improvement in EBIT, the overall lack of revenue and profitability presents significant challenges.

Balance Sheet

The balance sheet shows a strong equity position with no total debt reported in the latest period, resulting in a robust equity ratio. The company maintains a solid cash position, though the absence of revenue raises concerns about long-term sustainability. The return on equity remains negative due to ongoing net losses.

Cash Flow

Operating cash flow has been consistently negative, indicating challenges in generating cash from core operations. Despite positive financing activities that have bolstered cash reserves, the company struggles with negative free cash flow, which reflects ongoing operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	886.00K	2.33M	18.74M	0.00
Gross Profit	0.00	0.00	-78.00K	365.00K	16.74M	-1.62M
EBITDA	-214.36M	-207.97M	-127.82M	-83.21M	-63.66M	-79.27M
Net Income	-208.93M	-208.02M	-338.79M	-83.81M	-65.80M	-80.89M
Balance Sheet
Total Assets	569.78M	608.48M	341.86M	71.14M	109.93M	161.62M
Cash, Cash Equivalents and Short-Term Investments	564.82M	603.09M	339.28M	55.71M	93.13M	146.27M
Total Debt	0.00	0.00	84.56M	4.63M	5.06M	5.45M
Total Liabilities	87.17M	90.68M	157.84M	20.84M	25.98M	21.79M
Stockholders Equity	482.61M	517.80M	184.02M	50.30M	83.94M	139.83M
Cash Flow
Free Cash Flow	-169.86M	-157.41M	-99.91M	-80.18M	-54.29M	-80.06M
Operating Cash Flow	-169.86M	-157.41M	-99.91M	-80.14M	-53.72M	-75.78M
Investing Cash Flow	-248.38M	-353.29M	-108.39M	57.01M	-22.62M	-7.60M
Financing Cash Flow	238.87M	410.91M	361.08M	42.68M	1.39M	154.51M

Spyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 15.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRE, the sentiment is Neutral. The current price of 15.5 is below the 20-day moving average (MA) of 16.21, above the 50-day MA of 15.29, and below the 200-day MA of 22.11, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 48.30 is Neutral, neither overbought nor oversold. The STOCH value of 40.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SYRE.

Spyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NRIX	56 Neutral	$892.72M	―	-64.16%	―	-30.25%	-5.92%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
VIR	50 Neutral	$706.40M	―	-44.59%	―	-73.79%	-5.24%
ZYME	49 Neutral	$871.84M	―	-29.80%	―	85.05%	15.96%
RCUS	48 Neutral	$885.20M	―	-63.17%	―	-40.51%	-35.07%
SYRE	43 Neutral	$934.88M	2.31	-50.47%	―	-100.00%	94.68%
PHVS	42 Neutral	$940.01M	―	-51.85%	―	―	0.71%

Spyre Therapeutics Corporate Events

Spyre Therapeutics Faces Internal Control Challenges

In a rapidly changing financial landscape, our company has identified a significant weakness in our internal control over financial reporting, particularly affecting earnings per share calculations. This issue could lead to material misstatements, impacting our financial condition and stock price. Management is committed to improving controls and believes that remediation efforts will enhance existing systems, but failure to rectify these issues promptly could undermine investor confidence and affect our Nasdaq listing.

Spyre Therapeutics Reports Promising Trial Results for SPY001

Spyre Therapeutics announced the promising interim results from its Phase 1 trial of SPY001, a novel monoclonal antibody targeting α4β7 for the treatment of inflammatory bowel disease. The trial revealed that SPY001, with a half-life exceeding 90 days, was well-tolerated and showed potential for long-term maintenance dosing, either every three or six months. Spyre plans to begin a Phase 2 trial in mid-2025, aiming to enhance the efficacy of current treatments with this innovative therapy and other combinations.